Polymer blends having reverse phase morphology for controlled delivery of bioactive agents

Claim 2

A polymer blend of a soluble and insoluble polymer having reverse phase morphology wherein a soluble polymer phase comprises regions dispersed in a continuous insoluble polymer phase, said polymer blend comprising (a) up to about 40 percent by weight of an insoluble polymer of cellulose acetate containing greater than about 20 percent but less than 44 percent by weight of acetyl, and (b) greater than about 60 percent by weight of a soluble polymer selected from the group consisting of cellulose acetate phthalate, cellulose acetate trimellitate, and cellulose acetate succinate.

Claim 3

The polymer blend of claim 1 wherein said soluble polymer phase comprises regions having diameters of from about 1 μm to the thickness of the blend.

Claim 4

The polymer blend of claim 1 wherein said soluble polymer phase comprises regions having diameters of from about 1 μm to about 100 μm.

Claim 5

The polymer blend of claim 1 wherein the amount of insoluble polymer is from about 10 to about 35 percent by weight, and the amount of soluble polymer is from about 65 to about 90 percent by weight.

Claim 6

A composition comprising a polymer blend of a soluble and insoluble polymer having reverse phase morphology wherein a soluble polymer phase comprises regions dispersed in a continuous insoluble polymer phase, said polymer blend comprising (a) up to about 40 percent by weight of an insoluble polymer of cellulose acetate containing greater than about 20 percent but less than 44 percent by weight of acetyl, and (b) greater than about 60 percent by weight of a soluble polymer selected from the group consisting of cellulose acetate phthalate, cellulose acetate trimellitate, and cellulose acetate succinate; and an effective amount of a bioactive agent.

Claim 7

A composition comprising a polymer blend of a soluble and insoluble polymer having reverse phase morphology wherein a soluble polymer phase comprises regions dispersed in a continuous insoluble polymer phase, said polymer blend comprising (a) up to about 40 percent by weight of an insoluble polymer of cellulose acetate containing greater than about 20 percent but less than 44 percent by weight of acetyl, and (b) greater than about 60 percent by weight of a soluble polymer selected from the group consisting of cellulose acetate phthalate, cellulose acetate trimellitate, and cellulose acetate succinate; and an effective amount of a bioactive agent.

Claim 8

The composition of claim 5 wherein said effective amount is from about 1 percent to about 99 percent by weight of the total composition.

Claim 9

The composition of claim 5 wherein the bioactive agent is substantially dispersed in the soluble polymer.

Claim 10

The composition of claim 7 wherein said effective amount of bioactive agent is between about 10 and about 25 percent by weight.

Claim 11

The composition of claim 5 wherein the polymer blend coats a bioactive agent reservoir.

Claim 12

The composition of claim 9 wherein said effective amount of bioactive agent is between about 85 and 97 percent by weight.

Claim 13

The composition of claim 5 wherein the bioactive agent is a drug.

Claim 14

The composition of claim 5 wherein the bioactive agent is selected from the group consisting of adrenal cortical steroid inhibitors, analgesics, anorexics, anti-alcohol preparations, anti-arthritics, anti-infective drugs, autonomic drugs, anti-diabetic agents, anti-diarheals, anti-dimetrics, anti-flatulents, anti-herpes drugs, anti-histamines, anti-tussive agents, respiratory drugs, mucolytics, decongestants, bronchodilators, anti-inflammatory agents, anti-leprosy drugs, anti-motion sickness agents, anti-nauseants, anti-neoplastic drugs, anti-parkinsonism drugs, anti-psychotics, anti-spasmodics, anti-cholinergics, anti-vertigo agents, cardiovascular preparations, chealating agents, cholestrol reducers, contraceptives, diuretics, dopamine receptor agonists, electrolytes, ergot preparations, ferility agents, fluorine preparations, hematinics, histamine H 2 receptor antagonists, hormones, hypnotics, immunosuppressives, laxatives, muscle relaxants, narcotic antagonists, parasympathalytics, parasympathomimetrics, prostaglandine, quindines, central nervous system depressants, anti-depressants, stimulants, thyroid preparations, trace minerals, tranquilizers, X-ray contrast media, vitamins, minerals, enzymes, amino acids, proteins, digestive aids, herbicides, fertilizers, growth promotors, pesticides, nematocides, and fungicides.

Claim 15

The composition of claim 5 wherein the bioactive agent is selected from the group consisting of aspirin, acetaminophen, ibuprofin, codeine, morphine, amphetamine, erythromycin, epinephrine, bethanechol, atropine, scopolamine, mecamylamine, insulin, chloropheniramine maleate, dextromethorphan, syrup of ipecac, quaifenesin, phenylephrine, ephedrine, theophylline, phenylbutazones, salicylates steroids, 5-aminosalicylic acid, sulfasalazene, alpha receptor blocking agents, beta receptor blocking agents, anti-anginal drugs, anti-hypertensives, calcium channel blockers, digitalis, quindine, vasodialators, potassium chloride, anti-migrane agents, uterine contractants, chelated iron salts, non-chelated iron salts, cimitidine, ranitidine, fecal softeners, fecal stimulants, monoamine oxidase inhibitors, caffeine, nicotine, sodium amobarbital, flurazepam, chlordiazepoxide, diazepam, and lithum preparations.

Claim 16

The polymer blend of claim 1 additionally containing from about 0 percent to about 40 percent by weight of a plasticizer.

Claim 17

The composition of claim 5 additionally containing from about 0 percent to about 40 percent by weight of a plasticizer.

Claim 18

The polymer blend of claim 14 wherein the plasticizer is selected from the group consisting of diethylphthalate, dioctylphthalate, other mono- or di-alkylphthalates, glycerine, triacetin, and polyethylene glycol ethers.

Claim 19

The composition of claim 15 wherein the plasticizer is selected from the group consisting of diethylphthalate, dioctylphthalate, other mono- or di-alkylphthalates, glycerine, triacetin, and polyethylene glycol ethers.

Claim 20

The polymer blend of claim 1 wherein said cellulose acetate contains between about 32 and about 40 percent by weight acetyl; said cellulose acetate phthalate contains between about 19 and about 23 percent by weight acetyl and between about 32 and about 36 percent by weight phthalyl; said cellulose acetate trimetllitate contains between about 18 and about 26 percent by weight acetyl and between about 25 and about 33 percent by weight of trimellityl; and said cellulose acetate succinate contains between about 24 and about 28 percent by weight of acetyl and between about 14 and about 25 percent by weight of succinyl.

Claim 21

The composition of claim 5 that is formed into a device in the shape of a tablet, bead, granule, microparticle, fiber, or capsule.

Claim 22

The composition of claim 5 wherein the bioactive agent is pre-extracted for a time sufficient to reduce the burst effect and leave the zero-order release characteristics substantially unaffected.

Claim 23

A polymer matrix wherein a soluble polymer is extracted from a polymer blend of a soluble and insoluble polymer having reverse phase morphology wherein a soluble polymer phase comprises regions dispersed in a continuous insoluble polymer phase, leaving a matrix of insoluble polymer having pores of from about 1 to about 100 micrometers in diameter, said polymer blend comprising (a) up to about 40 percent by weight of an insoluble polymer of cellulose acetate containing greater than about 20 percent but less than 44 percent by weight of acetyl, and (b) greater than about 60 percent by weight of a soluble polymer selected from the group consisting of cellulose acetate phthalate, cellulose acetate trimellitate, and cellulose acetate succinate.

Claim 24

A polymer matrix wherein a soluble polymer is extracted from a polymer blend of a soluble and insoluble polymer having reverse phase morphology wherein a soluble polymer phase comprises regions dispersed in a continuous insoluble polymer phase, leaving a matrix of insoluble polymer having pores of from about 1 to about 100 micrometers in diameter, said polymer blend comprising (a) up to about 40 percent by weight of an insoluble polymer of cellulose acetate containing greater than about 20 percent but less than 44 percent by weight of acetyl, and (b) greater than about 60 percent by weight of a soluble polymer selected from the group consisting of cellulose acetate phthalate, cellulose acetate trimellitate, and cellulose acetate succinate.

Claim 25

The polymer matrix of claim 21 wherein said matrix is infused with a bioactive agent.

Claim 26

The polymer matrix of claim 22 wherein said bioactive agent is selected from the group consisting of adrenal cortical steroid inhibitors, analgesics, anorexics, anti-alcohol preparations, anti-arthritics, anti-infective drugs, autonomic drugs, anti-diabetic agents, anti-diarheals, anti-dimetrics, anti-flatulents, anti-herpes drugs, anti-histamines, anti-tussive agents, respiratory drugs, mucolytics, decongestants, bronchodilators, anti-inflammatory agents, anti-leprosy drugs, anti-motion sickness agents, anti-nauseants, anti-neoplastic drugs, anti-parkinsonism drugs, anti-psychotics, anti-spasmodics, anti-cholinergics, anti-vertigo agents, cardiovascular preparations, chealating agents, cholesterol reducers, contraceptives, diuretics, dopamine receptor agonists, electrolytes, ergot preparations, fertility agents, fluorine preparations, hematinics, histamine H 2 receptor antagonists, hormones, hypnotics, immunosuppressives, laxatives, muscle relaxants, narcotic antagonists, parasympathalytics, parasympathomimetrics, prostaglandine, quinidines, central nervous system depressants, anti-depressants, stimulants, thyroid preparations, trace minerals, tranquilizers, X-ray contrast media, vitamins, minerals, enzymes, amino acids, proteins, digestive aids, herbicides, fertilizers, growth promotors, pesticides, nematocides, and fungicides.

Claim 27

The polymer matrix of claim 22 wherein said bioactive agent is selected from the group consisting of aspirin, acetaminophen, ibuprofin, codeine, morphine, amphetamine, erythromycin, epinephrine, bethanechol, atropine, scopolamine, mecamylamine, insulin, chloropheniramine maleate, dextromethorphan, syrup of ipecac, quaifenesin, phenylephrine, ephedrine, theophylline, phenylbutazones, salicylates steroids, 5-aminosalicylic acid, sulfasalazene, alpha receptor blocking agents, beta receptor blocking agents, anti-anginal drugs, anti-hypertensive, calcium channel blockers, digitalis, quinidine, vasodialators, potassium chloride, anti-migrane agents, uterine contractants, chelated iron salts, non-chelated iron salts, cimitidine, ranitidine, fecal softeners, fecal stimulants, monoamine oxidase inhibitors, caffeine, nicotine, sodium amobarbital, flurazepam, chlordiazepoxide, diazepam, and lithum preparations.

Claim 30

The method of claim 25 wherein the amount of insoluble polymer is from about 10 to about 35 percent by weight, and the amount of soluble polymer is from about 65 to about 90 percent by weight.

Claim 31

The method of claim 25 wherein the bioactive agent of said composition is substantially dispersed in the soluble polymer.

Claim 32

The method of claim 27 wherein the effective amount of bioactive agent in said composition is between about 10 and about 35 percent by weight.

Claim 33

The method of claim 25 wherein the polymer blend of said composition coats a bioactive agent reservoir.

Claim 34

The method of claim 29 wherein the effective amount of said composition is between about 85 and 97 percent by weight.

Claim 35

The method of claim 25 wherein the bioactive agent of said composition is a drug.

Claim 36

The method of claim 25 wherein the bioactive agent of said composition is selected from the group consisting of adrenal cortical steroid inhibitors, analgesics, anorexics, anti-alcohol preparations, anti-arthirtics, anti-infective drugs, autonomic drugs, anti-diabetic agents, anti-diarheals, anti-dimetrics, anti-flatulents, anti-herpes drugs, anti-histamines, anti-tussive agents, respiratory drugs, mucolytics, decongestants, bronchodilators, anti-inflammatory agents, anti-leprosy drugs, anti-motion sickness agents, anti-nauseants, anti-neoplastic drugs, anti-parkinsonism drugs, anti-psychotics, anti-spasmodics, anti-cholinergics, anti-vertigo agents, cardiovascular preparations, chealating agents, cholesterol reducers, contraceptives, diuretics, dopamine receptor agonists, electrolytes, ergot preparations, ferility agents, fluorine preparations, hematinics, histamine H 2 receptor antagonists, hormones, hypnotics, immunosuppressives, laxatives, muscle relaxants, narcotic antagonists, parasympathalytics, parasympathomimetrics, prostaglandine, quinidines, central nervous system depressants, anti-depressants, stimulants, thyroid preparations, trace minerals, tranquilizers, X-ray contrast media, vitamins, minerals, enzymes, amino acids, proteins, digestive aids, herbicides, fertilizers, growth promotors, pesticides, nematocides, and fungicides.

Claim 37

The method of claim 25 wherein the bioactive agent of said composition is selected from the group consisting of aspirin, acetaminophen, ibuprofin, codeine, morphine, amphetamine, erythromycin, epinephrine, bethanechol, atropine, scopolamine, mecamylamine, insulin, chloropheniramine maleate, dextromethorphan, syrup of ipecac, quaifenesin, phenylephrine, ephedrine, theophylline, phenylbutazones, salicylates steroids, 5-aminosalicylic acid sulfasalazene, alpha receptor blocking agents, beta receptor blocking agents, anti-anginal drugs, anti-hypertensives, calcium channel blockers, digitalis, quinidine, vasodialators, potassium chloride, anti-migrane agents, uterine contractants, chelated iron salts, non-chelated iron salts, cimitidine, ranitidine, fecal softeners, fecal stimulants, monoamine oxidase inhibitors, caffeine, nicotine, sodium amobarbital, flurazepam, chlordiazepoxide, diazepam, and lithum preparations.

Claim 38

The method of claim 25 wherein said composition additionally contains from about 0 percent to about 40 percent by weight of a plasticizer.

Claim 39

The method of claim 34 wherein said plasticizer is selected from the group consisting of diethylphthalate, dioctylphthalate, other mono- or di-alkylphthalates, glycerine, triacetin, and polyethylene glycol ethers.

Claim 40

The method of claim 25 wherein said composition is formed into a device in the shape of a tablet, bead, granule, microparticle, fiber, or capsule.

Claim 41

The method of claim 25 wherein the bioactive agent of said composition is pre-extracted for a time sufficient to reduce the burst effect and leave the zero order release characteristics substantially unaffected.

Claim 44

The method of claim 38 wherein the bioactive agent of said polymer matrix is selected from the group consisting of adrenal cortical steroid inhibitors, analgesics, anorexics, anti-alcohol preparations, anti-arthritics, anti-infective drugs, autonomic drugs, anti-diabetic agents, anti-diarheals, anti-dimetrics, anti-flatulents, anti-herpes drugs, anti-histamines, anti-tussive agents, respiratory drugs, mucolytics, decongestants, bronchodilators, anti-inflammatory agents, anti-leprosy drugs, anti-motion sickness agents, anti-nauseants, anti-neoplastic drugs, anti-parkinsonism drugs, anti-psychotics, anti-spasmodics, anti-cholinergics, anti-vertigo agents, cardiovascular preparations, chealating agents, cholesterol reducers, contraceptives, diuretics, dopamine receptor agonists, electrolytes, ergot preparations, fertility agents, fluorine preparations, hematinics, histamine H 2 receptor antagonists, hormones, hypnotics, immunosuppressives, laxatives, muscle relaxants, narcotic antagonists, parasympathalytics, parasympathomimetrics, prostaglandine, quinidines, central nervous system depressants, anti-depressants, stimulants, thyroid preparations, trace minerals, tranquilizers, X-ray contrast media, vitamins, minerals, enzymes, amino acids, proteins, digestive aids, herbicides, fertilizers, growth promotors, pesticides, nematocides, and fungicides.

Claim 45

The method of claim 38 wherein the bioactive agent of said polymer matrix is selected from the group consisting of aspirin, acetaminophen, ibuprofin, codeine, morphine, amphetamine, erythromycin, epinephrine, bethanechol, atropine, scopolamine, mecamylamine, insulin, chloropheniramine maleate, dextromethorphan, syrup of ipecac, quaifenesin, phenylephrine, ephedrine, theophylline, phenylbutazones, salicylates steroids, 5-aminosalicylic acid, sulfasalazene, alpha receptor blocking agents, beta receptor blocking agents, anti-anginal drugs, anti-hypertensive, calcium channel blockers, digitalis, quinidine, vasodialators, potassium chloride, anti-migrane agents, uterine contractants, chelated iron salts, non-chelated iron salts, cimitidine, ranitidine, fecal softeners, fecal stimulants, monoamine oxidase inhibitors, caffeine, nicotine, sodium amobarbital, flurazepam, chlordiazepoxide, diazepam, and lithum preparations.